Vertaling van "treatment in relapsing " (Nederlands → Frans) :

TERMINOLOGIE

febris recurrens [Relapsing Fever]
Fièvres récurrentes [borrélioses]

IN-CONTEXT TRANSLATIONS

Gilenya was approved as a first-line treatment for relapsing forms of multiple sclerosis in the US and for relapsing remitting multiple sclerosis in Russia.
Gilenya a été autorisé aux Etats-Unis comme traitement de première ligne des formes cycliques de la sclérose en plaques et pour la même indication en Russie.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

The approval of Gilenya gives patients a new and convenient treatment option that has shown significant efficacy in reducing symptoms and preventing relapses.
Avec l’homologation de Gilenya, les malades disposent d’une nouvelle option commode qui a démontré son efficacité pour réduire les symptômes et prévenir les rechutes.

Gilenya (FTY720), the breakthrough oral treatment for relapsing forms of multiple sclerosis (MS), was launched in the United States in early October.
Gilenya (FTY720), le traitement innovateur par voie orale de la forme cyclique de la sclérose en plaques, a été lancé début octobre aux Etats-Unis.

In a significant breakthrough for patients suffering from multiple sclerosis (MS), Novartis gained US and Russian regulatory approval in the third quarter for Gilenya (FTY720), an effective, first-line oral treatment for relapsing multiple sclerosis, the most common form of the disease.
Dans une percée majeure pour les malades souffrant de sclérose en plaques, Novartis a obtenu, au troisième trimestre, une autorisation de mise sur le marché aux Etats-Unis et en Russie de Gilenya (FTY720), un traitement efficace de première ligne par voie orale contre la sclérose en plaques cyclique, la forme la plus commune de la maladie.

The FDA approved Gilenya, a novel, first-line oral treatment for relapsing forms of multiple sclerosis – the most common forms of the disease.
pour le traitement des formes cycliques, les plus communes, de la sclérose en plaques.

The FDA advisory committee unanimously recommended approval of FTY720 (fingolimod) as treatment in relapsing remitting multiple sclerosis, the most common form of the disease.
La recommandation unanime du comité consultatif de la FDA en faveur de l’autorisation de FTY720 (fingolimod) pour le traitement de la sclérose en plaques cyclique, la forme la plus répandue de cette maladie.

Relapse rate was het aandeel proefpersonen met een niet-detecteerbaar HCV-RNA bij End of Treatment (EOT) en een detecteerbaar HCV-RNA bij End of Follow-up (EOF) bij proefpersonen die niet detecteerbaar waren bij EOT en bij wie gegevens over EOF niet ontbraken.
Le taux de rechute était la proportion de sujets présentant un taux d’ARN-VHC indétectable à la fin du traitement (FDT) et un taux d’ARN-VHC détectable à la fin du suivi (FDS) parmi les sujets ayant un taux indétectable à la fin du traitement (FDT) et sans données manquantes à la fin du suivi (FDS).

(1) De volgende referentie publicatie van W. Kissling is bevestigd door recenter onderzoek: W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer-Verlag Berlin Heidelberg, 1991, pp95-107 (2) Zelfde referentie als 1.
(1) La publication de référence suivante de W. Kissling est confirmée par une étude plus récente : W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer Verlag Berlin Heidelberg, 1991, pp 95-107 (2) Même référence que pour 1.

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.